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Abstract 
Gastrointestinal  stromal  tumors  are  mes-
enchymal tumors of the gastrointestinal tract.
They  commonly  metastasize  within  the
abdominal cavity, particularly to the liver. Less
commonly,  metastases  can  be  found  in  the
lung or bone. This report describes the first
two cases of metastasis to the left ventricle in
patients with advanced gastrointestinal stro-
mal tumor.
Introduction 
Gastrointestinal stromal tumors (GISTs) are
the most common mesenchymal tumors of the
gastrointestinal tract, arising predominantly in
the  stomach  (60-70%),  small  intestine  (20-
25%), colon and rectum (5%), or esophagus
(<5%).
1 Approximately 90% of GISTs stain pos-
itively for the receptor tyrosine kinase, KIT (or
CD117). Eighty-five percent of tumors contain
mutations in KIT and 5% in PDGFRA.
2 GISTs
most commonly metastasize to the liver and
abdominal cavity.
3Extra-abdominal metastases
are extremely rare, with pulmonary and bone
metastases being the most frequent sites. We
report here the first two cases of metastatic
GIST to the left ventricle. 
Case Reports
Case #1
A 48-year-old healthy male presented with
abdominal  pain,  nausea,  vomiting,  diarrhea,
and a palpable abdominal mass. A computer
tomography (CT) scan revealed a large right
lower  quadrant  mass  with  liver  lesions.  He
underwent resection of a 21¥20¥13 cm mass
arising on the small intestine, a 5 cm right
colonic  mass,  as  well  as  the  small  bowel
mesentery and peritoneum diffusely infiltrated
by multiple nodular lesions. Morphological and
immunocytochemical  features  of  the  tumor
were consistent with GIST. 
After the surgical resection, imatinib ther  -
apy was administered at a dose of 400 mg daily,
initially  complicated  by  transient  transamin  -
itis. Eighteen months later, he was found to
have progressive liver metastases and his dose
of imatinib was increased to 600 mg daily, fol-
lowed  by  surgical  debulking  of  three  liver
lesions. Six months later, his daily dose was
increased  to  800  mg.  During  this  period  he
also underwent two courses of radio frequency
ablation of several liver lesions. The patient
was noted to have additional liver metastases
and  pulmonary  nodules  and  began  therapy
with  sunitinib.  He  was  started  on  a  clinical
trial  of  nilotinib  for  progressive  disease  six
months later.
On restaging studies following six weeks of
therapy, a CT scan of the chest, abdomen, and
pelvis  revealed  stable  pulmonary  metastases
and an increase in size of the multiple liver
metastases, minimally less than 20% progres-
sion  from  baseline.  It  also  demonstrated  a
2.5¥3.5 cm hypo-attenuating focus along the
inferior wall of the left ventricle (Figure 1),
which was found to be metabolically active on
positron emission tomography (PET) imaging
(Figure 2). Echocardiography was performed
to determine if the lesion was metastatic dis-
ease or a thrombus. The examination revealed
normal left ventricular size and function and
normal  left  ventricular  wall  thickness.  The
study confirmed the presence of a moderate-
sized mass attached to the inferior and apical
walls of the ventricle, consistent with metasta-
tic GIST. 
Case #2
A 61-year-old male with a history of type II
diabetes,  benign  prostatic  hypertrophy,  cor  -
onary artery disease, and hypertension, and a
family history notable for three brothers with
stomach  malignancies,  developed  abdominal
pain that was not relieved by antacids or pro-
ton pump inhibitors. He presented to his local
emergency  room  for  these  complaints  two
months  later  with  complaints  of  abdominal
pain. A CT scan demonstrated a 15 cm small
intestine mass that was abutting on the blad-
der.  He  underwent  resection  of  an  approxi-
mately 15.0 cm intra-abdominal mass with par-
tial cystectomy. The tumor was diagnosed as a
gastrointestinal leiomyosarcoma and no addi-
tional  therapy  was  given  at  that  time.  Five
years later, the patient noticed abdominal full-
ness. He was found to have a local recurrence,
which was resected. 
A  second  recurrence  was  diagnosed  two
years later. At this time, the patient’s path  ology
was  reviewed.  His  pathologic  diagnosis  was
changed to GIST, a mixed spindle- and epithe-
lioid-cell neoplasm with a diffuse intermediate
positive staining for c-KIT and diffusely strong-
ly positive staining for SMA and vimentin. He
was  treated  with  imatinib,  400  mg  daily,
achieving  stable  disease.  He  had  a  surgical
resection of the recurrent GIST that same year.
Three years later, while on imatinib, he devel-
oped back pain and a repeat CT was performed.
He was found to have multiple pelvic metas-
tases that occluded his left ureter. An echocar-
diogram performed in anticipation of sunitinib
therapy  revealed  a  5¥2.5  cm  left  ventricular
wall mass. A magnetic resonance image (MRI)
of the heart (Figure 3) revealed a lesion that
appeared to be attached to the lateral mid left
ventricular  wall,  separate  from  the  valves,
measuring  3.8¥3.3¥3.9  cm,  which  was  most
likely a metastatic focus. The patient has been
started on sunitinib, 37.5 mg daily; complicat-
ed by a deep venous thrombosis, pulmonary
embolism, and atrial fibrillation.
Discussion
The term GIST was first coined by Mazur
and Clark in 1983 to include a heterogeneous
group of non-epithelial neoplasms of the gas-
trointestinal tract.
4Surgery has been the main-
stay of therapy with limited benefit from radia-
tion and cytotoxic chemotherapy.
5 Despite suc-
cessful surgical therapy, GISTs exhibit a high
risk for metastatic relapse, predominantly local
recurrences, liver, and peritoneal metastases.
The  median  disease-specific  survival  in
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patients with recurrent and metastatic GIST
has  been  reported  to  be  12  and  19  months,
respectively.
6
In  1998,  Hirota  et  al.
7 identified  gain-of-
function mutations of the KIT proto-oncogene
in  the  majority  of  GISTs.  Similar  activating
mutations have been identified in PDGFRA.
8
Imatinib was the first targeted agent studied
in advanced GISTs. It inhibits several receptor
tyrosine kinases including KIT, PDGFRA, and
PDGFRB. Data from a pooled analysis of the
phase III trials comparing 400 mg/day and 800
mg/day imatinib doses indicated no statistical-
ly significant differences in median progres-
sion-free survival or overall survival, except for
those whose tumors carried an exon 9 muta-
tion, in which there was a benefit in progres-
sion-free survival at the higher dose.
9 In the
advanced and metastatic settings, imatinib at
an initial dose of 400 mg/day is standard first-
line  therapy,  with  dose  escalation  up  to 
800 mg/day in those with mutations in exon 9
or disease progression at the lower dose.
10
Sunitinib inhibits multiple receptor tyrosine
kinases including KIT, PDGFRA and PDGFRB,
VEGFR-1,  VEGFR-2  and  VEGFR-3,  FMS-like
tyrosine  kinase-3  receptor,  the  receptor  for
macrophage  colony-stimulating  factor,  and
glial  cell  line-derived  neurotrophic  factor
receptor.
11 A completed phase III study random-
ized patients to placebo or sunitinib in a dou-
ble-blinded trial in advanced GIST resistant to
800 mg/day imatinib or intolerant of imatinib,
with crossover to sunitinib at the time of pro-
gression for patients on the placebo.
12 At the
initial interim analysis, median time to pro-
gression  for  the  placebo  and  the  sunitinib
groups were significantly different (1.5 vs. 6
months, respectively), leading to termination
of the study and crossover of patients on the
placebo. There was an 8% partial response in
the  sunitinib  arm  compared  to  none  in  the
placebo  group.  Additional  agents  are  being
tested for treatment in the third line setting.
Nilotinib, the investigational agent in case #1,
is  a  second  generation  aminopyrimidine
inhibitor of KIT, PDGFR, and BCR-ABL. A phase
I trial of nilotinib in GIST has demonstrated
safety  and  clinical  benefit  in  patients  with
imatinib and sunitinib refractory disease.
13
Targeted  therapies  have  dramatically
improved the outcomes in GIST. Patients are
living  longer  with  metastatic  disease.  With
longer survival and the use of palliative ther  -
apies,  new  sites  of  metastases  are  being
reported.  One  case  report  describes  brain
metastases following an initial presentation of
a  jejunal  GIST  with  liver  metastases.
14
Interestingly,  this  patient  had  received  only
surgery and cytoreductive chemotherapy, and
had  not  received  tyrosine  kinase  inhibitor
therapy prior to this diagnosis. The patient was
palliated  successfully  with  imatinib  for  15
months before further progression. There is
also a case report of a testicular metastasis.
15
Lastly, lymph node metastases are said to be
uncommon  at  primary  disease  presentation
but,  as  was  seen  in  this  patient,  can  be
observed in patients with metastatic disease.
Our report is of interest because extra-abdom-
inal  metastases  are  uncommon.  This  report
describes  the  first  documented  cases  of
metastatic GIST to the heart.  
In conclusion, the occurrence of a cardiac
metastasis, in our opinion, is not the result of
the therapy that these patients received but
rather of prolonged metastatic disease palliat-
ed by multiple modalities. The availability of
imatinib, sunitinib, and several other promis-
ing investigational therapies, either alone or
in combination, is leading to increasingly pro-
longed survival and “new” sites of disease.   
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